Clinical Trial Update: A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) [Phase 3]

View source ↗

Summary

A randomized Phase 3 trial evaluating VRDN-001 for Thyroid Eye Disease has completed, including safety and tolerability assessments.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• VRDN-001

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: COMPLETED